No Prescription |
 |
 | ||
|
TAGON Zelnorm |
|
| ||
No Prescription » Prescription Drugs 15 » TAGON Zelnorm This medication is used to treat irritable bowel syndrome (IBS) in women who have constipation as a major symptom. Tegaserod relieves constipation by shortening the time stool remains in the bowel reducing stomach pain and bloating. It is also used in women with severe long-term constipation. Use of tegaserod is FDA-restricted to women less than 55 years of age who have tried other treatments for constipation without relief and who are free of heart disease (see also Side Effects and Precautions sections).This medication should not be used to treat IBS in women who have diarrhea as their major symptom or if you currently have diarrhea or a history of frequent diarrhea.This medication has not been shown to work in men with IBS.How to use Tegaserod Hydrogen Maleate OralTake this medication by mouth usually twice daily before meals; or as directed by your doctor. Take this medication for 4 to 6 weeks. If your symptoms improve your doctor may recommend a second 4 to 6 weeks of treatment.What conditions does this medication treat?Tegaserod Hydrogen Maleate Oral may also be used to treat:Chronic Difficulty having a Bowel Movement Constipation Predominant Irritable Colon Buy TAGON Zelnorm and other Prescription Drugs 15 products online at Medstore. Buy Online at Medstore - Click Here!
About TAGON Zelnorm: Product Type: Prescription Drugs 15 TAGON ( Zelnorm Generic TEGASEROD ) TAGON (Zelnorm Generic TEGASEROD) Zelnorm Generic TEGASEROD 2mg Zelnorm Generic TEGASEROD TAGON
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
